ImmuPharma PLC (AIM:IMM)'s (LON:IMM) Tim McCarthy caught up with Proactive London after recently announcing a corporate overhaul aimed at saving £1.1m per year from 2022 and said it is preparing for late-stage trials for its lead asset.
The reorganisation will see ImmuPharma France SA and Ureka SAS merge into one company, based at the firm’s R&D facility in Bordeaux, France.
Their lead asset Lupuzor is being developed for the treatment of the autoimmune disease Lupus and ImmuPharma together with partner Avion Pharma is readying to take the drug into a phase III trial.